60 degrees pharmaceuticals study results published by new microbes and new infections demonstrate tafenoquine exhibits broad spectrum antifungal activity

Washington, aug. 30, 2023 (globe newswire) -- 60 degrees pharmaceuticals , inc. (“60p”) (nasdaq: sxtp), specialists in developing and marketing medicines for infectious diseases, today announced the journal, new microbes and new infections , has published non-clinical study results showing tafenoquine exhibits broad spectrum antifungal activity, including against candida spp. in cell culture, and decreases fungal burden in the lungs in an invasive pulmonary model of rhizopus in mice.
SXTP Ratings Summary
SXTP Quant Ranking